Skip to main content
Fig. 2 | BMC Urology

Fig. 2

From: Tislelizumab in combination with gemcitabine plus cisplatin chemotherapy as first-line adjuvant treatment for locally advanced or metastatic bladder cancer: a retrospective study

Fig. 2

Kaplan–Meier estimates of the progression-free survival (PFS) in the tislelizumab in combination with gemcitabine plus cisplatin (TGC) and gemcitabine plus cisplatin (GC) groups. PFS, progression-free survival; TGC, tislelizumab plus gemcitabine and cisplatin; GC, gemcitabine and cisplatin; HR, hazard ratio; CI, confidence interval

Back to article page

BMC Urology

ISSN: 1471-2490

Contact us